gmp
gmp

Find Clinical Drug Pipeline Developments & Deals by Lumen Bioscience

Loading...

All Data

Filters Filter refresh
×
FILTER DATA :
Therapeutic Area filter
    Study Phase filter
      Country filter
        News Type filter
          Company filter
            refresh

            Companies By Therapeutic Area Full Screen

            Development Status Full Screen

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Camelid antibodies

            Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed

            Highest Development Status: Preclinical Product Type: Large molecule

            Partner/Sponsor/Collaborator: USAMRDC

            Deal Size: $4.0 million Upfront Cash: Undisclosed

            Deal Type: Funding September 24, 2020

            Details:

            The grant supports rapid development of an oral SARS-CoV-2 treatment and preventative product candidates through FDA Investigational New Drug (IND) submission and initial engineering work for a large-scale cGMP manufacturing plant.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): LMN-101

            Therapeutic Area: Infections and Infectious Diseases Product Name: LMN-101

            Highest Development Status: Phase I Product Type: Large molecule

            Partner/Sponsor/Collaborator: WestRiver Management

            Deal Size: $16.0 million Upfront Cash: Undisclosed

            Deal Type: Series B Financing September 01, 2020

            Details:

            The round brings Lumen’s total equity and non-dilutive investment to $68 million and will support continued advancement of Lumen’s three clinical programs for C. difficile, norovirus and traveler’s diarrhea.